Projects & Grants
| Monitoring the immune system of hematooncological patients undergoing treatment with chimeric antigen receptor T-cells and treatment with bispecific or trispecific monoclonal antibody (bsAb or triAb) | |
|---|---|
| Project Id | SGS15/LF/2024 |
| Main solver | MUDr. Jana Mihályová |
| Period | 1/2024 - 12/2024 |
| Provider | Specifický VŠ výzkum |
| State | solved |
| Anotation | Treatment with chimeric antigen receptor T-cell therapy (CAR-T cells) and bispecific or trispecific monoclonal antibody (bsAb and triAb) is gradually becoming the standard of care for hematooncological patients, especially those with B-lymphoproliferative disease. The fundamental principle of both treatment modalities is to activate the patient's own immune system to distinguish and destroy malignant cells. An increase in the number of cytokines leads to the activation of different immune cells. The part of cytokines produced also impact the development and duration of specific adverse effects. The effect of cytokines on the treatment response has not been defined yet. In the first year of our project, we focused on sample collection and archivation. We analyzed the cytokine profile of patients with B-cell non-Hodgkin lymphomas (B-NHL) and multiple myeloma (MM). In the second year, we will expand our analyses of patients with chronic lymphocytic leukemia (CLL) including Richter transformation. Based on changes in cytokine profiles before, during and after treatment, we will try to identify a subgroup of patients who could benefit from immunotherapy and those who could develop severe adverse events. Moreover, we will continue to archive samples for further clinical research. |
